Protalix BioTherapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure

Other Events

Regulation FD Disclosure

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Other Events

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 (amendment)

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Schwartz Aharon

Naos Yaron

Bar-Shalev Amos

Boudes Pol F

Melincoff Gwen A

Bashan Dror

Forster Eliot

Ben Zvi Shmuel

Elze Christian

BlackRock, Inc.

Mamlok Gilad

MAK Capital Fund LP

MAK Capital Fund LP

Bashan Dror

Bar-Shalev Amos

Melincoff Gwen A

Boudes Pol F

Bar-Shalev Amos

Naos Yaron

Bashan Dror

Annual Report Scanned (Paper)

Correspondence with the SEC

Annual Report Scanned (Paper)

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No description available

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC